Eyeing Both A Partnership And An IPO, Aragon Takes $42M Series C

A well-connected fund that invests on behalf of a group of high-net-worth investors provides cash to complete a Phase II trial on prostate cancer drug ARN-509, and bring a breast cancer drug into the clinic.